Lexaria Bioscience Corp. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Discontinued Operations (Details 1)

Discontinued Operations (Details 1) - USD ($)	9 Months Ended
Discontinued Operations (Details 1) - USD ($)	May 31, 2021	May 31, 2020
Discontinued Operations And Disposal Groups Abstract
Revenue	$ 3,000	$ 114,750
Operating Expenses	(25,000)	(30,795)
Net income	$ (22,000)	$ 83,795

- Definition

Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References + Details